Clinical Trial Update: OnabotulinumtoxinA for the Treatment of New Daily Persistent Headache: an Open Label Study [Phase 2]

View source ↗

Summary

This is a Phase 2 open-label study evaluating Botox (onabotulinumtoxinA) for New Daily Persistent Headache, sponsored by St. Luke's-Roosevelt Hospital Center. T…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• New Daily Persistent Headache

Drugs mentioned

• Botox (OnabotulinumtoxinA)

Snippet

Sponsor: St. Luke's-Roosevelt Hospital Center | Conditions: New Daily Persistent Headache | Phase 2 | Status: TERMINATED